Report: Biotech licensing, M&A deals dropped in 2012

04/1/2013 | Genetic Engineering & Biotechnology News

Biotech and biopharmaceutical firms struck fewer licensing and acquisition deals in 2012 compared with 2011, perhaps fueled by greater confidence in drug pipelines and fewer worries about patent expirations, according to a new report from EP Vantage. Total licensing-deal value declined 19%, to $20.9 billion, and the number of products licensed dropped from 1,037, to 759. Merger and acquisition deals reached $42.6 billion, down 24%.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN